



SAFETY DATA SHEET

Revision date 16-Feb-2023

Version 6

Page 1 / 10

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name TRUMENBA (Meningococcal Group B Vaccine) Suspension for intramuscular injection

Product Code(s) WR00037

Synonyms TRUMENBA- neisseria meningitidis serogroup b recombinant lp2086 a05 protein variant antigen and neisseria meningitidis serogroup b recombinant lp2086 b01 protein variant antigen injection, suspension ; PF-05212366 (Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein [rLP2086; subfamily A and B; E coli] Vaccine); rLP2086; MnBvLP2086

Trade Name: TRUMENBA

Compound Number PF-05212366

Chemical Family: Not determined

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Vaccine

1.3. Details of the supplier of the safety data sheet

Pfizer Inc
66 Hudson Boulevard East
New York, New York 10001
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Not classified as hazardous according to Regulation (EC) 1272/2008 and/or other applicable regulations.

2.2. Label elements

Signal word Not Classified

Hazard statements Not classified in accordance with international standards for workplace safety.

Supplemental Hazard Compound, not fully tested, additional hazards may exist.

2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which

SAFETY DATA SHEET

Product Name TRUMENBA (Meningococcal Group B Vaccine)
Suspension for intramuscular injection
Revision date 16-Feb-2023

Page 2 / 10

Version 6

require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

NonHazardous

| Chemical name | Weight-% | REACH Registration Number | EC No | Classification according to Regulation (EC) No. 1272/2008 [CLP] | Specific concentration limit (SCL) | M-Factor | M-Factor (long-term) |
|---|----------|---------------------------|------------|---|------------------------------------|-------------------|----------------------|
| SODIUM CHLORIDE (CAS #: 7647-14-5) | * | - | 231-598-3 | Not classified as hazardous | Not Listed | No data available | No data available |
| MnB Bivalent rLP2086 (CAS #: PROPRIETARY) | * | | Not Listed | Not classified as hazardous | Not Listed | No data available | No data available |
| L-Histidine (CAS #: 71-00-1) | * | - | 200-745-3 | Not classified as hazardous | Not Listed | No data available | No data available |
| Polysorbate 80 (CAS #: 9005-65-6) | * | - | 500-019-9 | Not classified as hazardous | Not Listed | No data available | No data available |

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

| Chemical name | Oral LD50 | Dermal LD50 | Inhalation LC50 - 4 hour - dust/mist - mg/L | Inhalation LC50 - 4 hour - vapor - mg/L | Inhalation LC50 - 4 hour - gas - ppm |
|---------------------------|------------|-------------------|---|---|--------------------------------------|
| SODIUM CHLORIDE 7647-14-5 | 3000 | 10000 | No data available | No data available | No data available |
| L-Histidine 71-00-1 | 15000 | No data available | No data available | No data available | No data available |
| Polysorbate 80 9005-65-6 | 34.5 mL/kg | No data available | No data available | No data available | No data available |

Additional information

* Proprietary

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

SAFETY DATA SHEET

Product Name TRUMENBA (Meningococcal Group B Vaccine)
Suspension for intramuscular injection
Revision date 16-Feb-2023

Page 3 / 10

Version 6

4.1. Description of first aid measures

| | |
|---------------------|--|
| Inhalation | Remove to fresh air. Seek immediate medical attention/advice. |
| Eye contact | Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician. |
| Skin contact | Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention. |
| Ingestion | Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately. |

4.2. Most important symptoms and effects, both acute and delayed

| | |
|--|--|
| Most important symptoms and effects | For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information. |
|--|--|

4.3. Indication of any immediate medical attention and special treatment needed

| | |
|---------------------------|-------|
| Note to physicians | None. |
|---------------------------|-------|

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

| | |
|-------------------------------------|---|
| Suitable Extinguishing Media | Dry chemical, CO2, alcohol-resistant foam or water spray. |
|-------------------------------------|---|

5.2. Special hazards arising from the substance or mixture

| | |
|---|---|
| Specific hazards arising from the chemical | Fine particles (such as mists) may fuel fires/explosions. |
|---|---|

| | |
|--------------------------------------|--|
| Hazardous combustion products | Formation of toxic gases is possible during heating or fire. |
|--------------------------------------|--|

5.3. Advice for firefighters

| | |
|---|--|
| Special protective equipment for fire-fighters | Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment. |
|---|--|

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

| | |
|---------------------------------|--|
| Personal precautions | Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure. |
| For emergency responders | Use personal protection recommended in Section 8. |

6.2. Environmental precautions

| | |
|----------------------------------|--|
| Environmental precautions | Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release. |
|----------------------------------|--|

6.3. Methods and material for containment and cleaning up

| | |
|--|---|
| Methods for containment | Prevent further leakage or spillage if safe to do so. |
| Methods for cleaning up | Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly. |
| Prevention of secondary hazards | Clean contaminated objects and areas thoroughly observing environmental regulations. |

SAFETY DATA SHEET

Product Name TRUMENBA (Meningococcal Group B Vaccine)
Suspension for intramuscular injection
Revision date 16-Feb-2023

Page 4 / 10

Version 6

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Restrict access to work area. A change area to facilitate 'good laboratory/manufacturing' decontamination practices is recommended. Additional controls (based on risk assessment) should be implemented where open handling is required. Use enclosed manufacturing processing strategies. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Vaccine.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

SODIUM CHLORIDE

| | |
|--------|--------------------------|
| Latvia | 5 mg/m ³ |
| Russia | MAC: 5 mg/m ³ |

L-Histidine

| | |
|--------|---------------------|
| Latvia | 5 mg/m ³ |
|--------|---------------------|

Pfizer Occupational Exposure Band (OEB) Statement: The Vaccines Occupational Exposure Band (V-OEB) is a classification that has been assigned to biotechnology-based vaccines and antigen components. Risk assessments should be performed to assess potential exposures and determine appropriate controls.

SODIUM CHLORIDE

| | |
|--|--|
| Pfizer Occupational Exposure Band (OEB): | OEB 1 (control exposure to the range of 1000ug/m ³ to 3000ug/m ³) |
|--|--|

8.2. Exposure controls

Engineering controls

Release prevention and exposure protection measures should be established for any activities involving this material, as determined by a risk assessment conducted using appropriate Occupational Hygiene Risk Assessment tools. The containment level required for the activity should be based on the conclusions of the risk assessment. Where warranted, engineering controls, such as biosafety cabinets, should be applied as the primary means to control exposures.

Environmental exposure controls No information available.

Personal protective equipment Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety

SAFETY DATA SHEET

Product Name TRUMENBA (Meningococcal Group B Vaccine)
Suspension for intramuscular injection
Revision date 16-Feb-2023

Page 5 / 10

Version 6

equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

| | |
|---------------------------------------|---|
| Eye/face protection | Wear safety glasses as minimum protection (goggles recommended). (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.). |
| Hand protection | Wear impervious gloves, (e.g. Nitrile, etc.) to prevent skin contact. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.). |
| Skin and body protection | Wear impervious disposable protective clothing when handling this compound. Full body protection is recommended (scale dependent). (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.). |
| Respiratory protection | If operating and handling conditions result in airborne exposure, wear an appropriate respirator with a protection factor sufficient to control exposures (e.g. particulate cartridge with a full face respirator, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.). |
| General hygiene considerations | Handle in accordance with good industrial hygiene and safety practice. |

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

| | |
|---------------------------------------|---------------------------|
| Physical state | Liquid |
| Color | Clear |
| Odor | No information available. |
| Odor threshold | No information available |
| Molecular formula | Mixture |
| Molecular weight | Mixture |
| Property | Values |
| pH | 6.5 - 8.5 |
| Melting point / freezing point | No data available |
| Boiling point / boiling range | |
| Flash point | No information available |
| Evaporation rate | No data available |
| Flammability (solid, gas) | No data available |
| Flammability Limit in Air | |
| Upper flammability limit: | No data available |
| Lower flammability limit: | No data available |
| Vapor pressure | No data available |
| Vapor density | No data available |
| Relative density | No data available |
| Water solubility | No data available |
| Solubility(ies) | No data available |
| Partition coefficient | No data available |
| Autoignition temperature | No data available |
| Decomposition temperature | No data available |
| Kinematic viscosity | No data available |
| Dynamic viscosity | No data available |
| Particle characteristics | |
| Particle Size | No information available |
| Particle Size Distribution | No information available |
| Explosive properties | No information available |

SAFETY DATA SHEET

Product Name TRUMENBA (Meningococcal Group B Vaccine)
Suspension for intramuscular injection
Revision date 16-Feb-2023

Page 6 / 10

Version 6

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

| | |
|--|--|
| General Information: | Toxicological properties of the formulation have not been fully investigated. The information included in this section describes the potential hazards of the individual ingredients |
| Short term | In the event of accidental injection, an allergic reaction may occur. If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted. |
| Known Clinical Effects: | Based on clinical trials in humans, possible adverse effects following exposure to this compound may include: drowsiness, headache, diarrhea, vomiting, muscle pain, joint pain, fever, injection site pain. |
| Acute toxicity | Based on available data, the classification criteria are not met. |
| Serious eye damage/eye irritation | Based on available data, the classification criteria are not met. |
| Skin corrosion/irritation | Based on available data, the classification criteria are not met. |
| Respiratory or skin sensitization | Based on available data, the classification criteria are not met. |
| STOT - single exposure | Based on available data, the classification criteria are not met. |
| STOT - repeated exposure | Based on available data, the classification criteria are not met. |
| Reproductive toxicity | Based on available data, the classification criteria are not met. |
| Germ cell mutagenicity | Based on available data, the classification criteria are not met. |
| Carcinogenicity | Based on available data, the classification criteria are not met. |
| Aspiration hazard | Based on available data, the classification criteria are not met. |

Acute Toxicity: (Species, Route, End Point, Dose)

SAFETY DATA SHEET

Product Name TRUMENBA (Meningococcal Group B Vaccine)
Suspension for intramuscular injection
Revision date 16-Feb-2023

Page 7 / 10

Version 6

SODIUM CHLORIDE

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m³
Rat Oral LD 50 3 g/kg
Mouse Oral LD 50 4 g/kg
Rabbit Dermal LD 50 > 10 g/kg

L-Histidine

Rat Oral LD 50 > 15 g/kg
Rat Para-periosteal LD 50 > 2 g/kg
Mouse Oral LD 50 > 15 g/kg
Mouse Intravenous LD 50 > 2 g/kg

Polysorbate 80

Rat Intravenous LD 50 1790 mg/kg
Mouse Oral LD 50 25 g/kg

| Chemical name | Oral LD50 | Dermal LD50 | Inhalation LC50 |
|-----------------|---------------------|--------------------------|-----------------------|
| SODIUM CHLORIDE | = 3 g/kg (Rat) | > 10000 mg/kg (Rabbit) | > 42 mg/L (Rat) 1 h |
| L-Histidine | > 15 g/kg (Rat) | - | - |
| Polysorbate 80 | = 34.5mL/kg (Rat) | - | - |

Irritation / Sensitization: (Study Type, Species, Severity)

SODIUM CHLORIDE

Skin irritation Rabbit Mild
Eye irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

MnB Bivalent rLP2086

9 Week(s) Rabbit Intramuscular 400 ug/dose/2weeks NOAEL None identified

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

MnB Bivalent rLP2086

Fertility and Embryonic Development Rabbit Intramuscular * 200 ug/dose NOAEL No effects at maximum dose,
Reproductive toxicity, Developmental toxicity

Reproductive & Development

Toxicity Comments:

MnBrLP2086: * NOTE: 4 doses -17 and 4 days prior to mating, gestation days 10 and 24.

Carcinogenicity

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects

No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview:

Releases to the environment should be avoided. Environmental properties of the formulation

SAFETY DATA SHEET

Product Name TRUMENBA (Meningococcal Group B Vaccine)
Suspension for intramuscular injection
Revision date 16-Feb-2023

Page 8 / 10

Version 6

have not been investigated.

12.1. Toxicity

No information available

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

| Chemical name | PBT and vPvB assessment |
|-----------------|---|
| SODIUM CHLORIDE | The substance is not PBT / vPvB PBT assessment does not apply |
| L-Histidine | The substance is not PBT / vPvB |

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transportation as per defining criteria in the international transportation regulations and the shipper's knowledge of the material.

UN number: Not applicable

SAFETY DATA SHEET

Product Name TRUMENBA (Meningococcal Group B Vaccine)
Suspension for intramuscular injection
Revision date 16-Feb-2023

Page 9 / 10

Version 6

UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable

Special precautions for user: Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

SODIUM CHLORIDE

| | |
|---|------------|
| CERCLA/SARA Section 313 de minimus % | Not Listed |
| California Proposition 65 | Not Listed |
| TSCA | Present |
| EINECS | 231-598-3 |
| AICS | Present |

MnB Bivalent rLP2086

| | |
|---|------------|
| CERCLA/SARA Section 313 de minimus % | Not Listed |
| California Proposition 65 | Not Listed |
| EINECS | Not Listed |

L-Histidine

| | |
|---|------------|
| CERCLA/SARA Section 313 de minimus % | Not Listed |
| California Proposition 65 | Not Listed |
| TSCA | Present |
| EINECS | 200-745-3 |
| AICS | Present |

Polysorbate 80

| | |
|---|------------|
| CERCLA/SARA Section 313 de minimus % | Not Listed |
| California Proposition 65 | Not Listed |
| TSCA | Present |
| EINECS | Not Listed |
| AICS | Present |

France

Occupational Illnesses (R-463-3, France)

| Chemical name | French RG number | Title |
|------------------------------|------------------|-------|
| SODIUM CHLORIDE 7647-14-5 | RG 78 | - |

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

SAFETY DATA SHEET

Product Name TRUMENBA (Meningococcal Group B Vaccine)
Suspension for intramuscular injection
Revision date 16-Feb-2023

Page 10 / 10

Version 6

Plant protection products directive (91/414/EEC)

| Chemical name | Plant protection products directive (91/414/EEC) |
|-----------------------------|--|
| SODIUM CHLORIDE - 7647-14-5 | Plant protection agent |

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information.

Revision date 16-Feb-2023

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.